Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (3): 339-347.doi: 10.12092/j.issn.1009-2501.2024.03.013

Previous Articles     Next Articles

The attenuating and potentiating effects of traditional Chinese medicine in immune checkpoint therapy

ZHANG Zhipeng1, CHEN Ziqi2, TIAN Jianhui1,3   

  1. 1Oncology Research Center of Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China; 2Laboratory Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China; 3Oncology Clinical Research Center of Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China
  • Received:2023-09-20 Revised:2023-12-12 Online:2024-03-26 Published:2024-02-29

Abstract:

Immunotherapy has become a global focus in cancer clinical practice and scientific research.In the past two years, PD-1\PD-L1 and CTLA-4 inhibitors, especially Nivolumab, Pembrolizumab, Atezolizumab and Lpilimumab, have been used in non-small cell lung cancer, colon cancer. Promising results have been obtained in malignancies such as melanoma and urinary tract cancer. Traditional Chinese medicine has a long history in China. Modulating immune checkpoints has certain advantages in treating malignant tumors, and it has shown good efficacy in improving its adverse events. This article reviews the role of traditional Chinese medicine in regulating immune checkpoints and improving adverse reactions and its application prospects in immunomodulatory treatment.

Key words: traditional Chinese medicine, malignant tumours, immune checkpoint, immunotherapy, adverse reaction

CLC Number: